Union Bancaire Privee UBP SA Sells 15,518 Shares of Moderna, Inc. $MRNA

Key Points

• Union Bancaire Privee UBP SA reduced its stake in Moderna, Inc. by 70.5%, selling 15,518 shares and leaving it with 6,497 shares valued at $179,000.
• Institutional ownership of Moderna stock has reached 75.33%, with recent significant stake acquisitions by several firms, including Jump Financial LLC, which increased its investment by 5,590%.
• Analysts have mixed ratings on Moderna, with a consensus rating of "Hold" and a price target of $41.81, despite a recent drop in the price target by some brokerages.

Union Bancaire Privee UBP SA cut its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 70.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,497 shares of the company's stock after selling 15,518 shares during the period. Union Bancaire Privee UBP SA's holdings in Moderna were worth $179,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MRNA. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in Moderna in the first quarter valued at approximately $28,350,000. Jacobs Levy Equity Management Inc. acquired a new position in Moderna in the first quarter valued at approximately $28,308,000. Jump Financial LLC lifted its stake in Moderna by 5,590.0% in the first quarter. Jump Financial LLC now owns 902,427 shares of the company's stock valued at $25,584,000 after buying an additional 886,567 shares during the period. Invesco Ltd. lifted its stake in Moderna by 17.5% in the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after buying an additional 877,162 shares during the period. Finally, Sessa Capital IM L.P. acquired a new position in Moderna in the first quarter valued at approximately $21,066,000. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRNA. Leerink Partners dropped their price target on Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research note on Friday, August 22nd. Morgan Stanley reissued an "equal weight" rating and issued a $32.00 price target on shares of Moderna in a research note on Friday, August 1st. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. JPMorgan Chase & Co. set a $26.00 price target on Moderna in a research note on Friday, August 1st. Finally, Cowen began coverage on Moderna in a research report on Sunday, July 13th. They set a "hold" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, fourteen have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $41.81.

Moderna Stock Up 6.9%

Shares of NASDAQ:MRNA opened at $27.60 on Thursday. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $63.69. The stock's 50 day moving average is $26.52 and its 200-day moving average is $27.49. The firm has a market capitalization of $10.74 billion, a price-to-earnings ratio of -3.67 and a beta of 2.01.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.Moderna's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.